Rosetta Genomics this week announced that it has licensed the exclusive distribution rights to its three microRNA-based diagnostics in India, Saudi Arabia, Qatar, and the United Arab Emirates to India’s Super Religare Laboratories.
Under the deal, Super Religare will market Rosetta's miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.
Tissue samples will be sent from Super Religare’s territories to Rosetta’s Philadelphia-based laboratory for analysis. Additional terms of the arrangement were not disclosed.
News of the deal comes just days after Rosetta said it had licensed the diagnostics’ Canadian market rights to Warnex Medical Laboratories (see RNAi News, 8/13/2009).
In April, Rosetta signed a deal giving Prometheus Laboratories the US rights to the three tests (see RNAi News, 4/16/2009). In January, it licensed the Israeli and Turkish rights to Teva Pharmaceuticals (see RNAi News, 1/8/2009).